L&C Bio, a regenerative medicine company specializing in human tissue, showcased its ECM-based therapy Re2O at the Korean Academy of Anti-Aging Dermatology (KAAD) 2026 Summer Conference, highlighting a shift from short-term aesthetic fixes to long-term skin health. For overseas buyers and distributors, this signals growing clinical validation and market potential for human-derived acellular dermal matrix (hADM) products in aesthetic and regenerative applications.
## ECM Session Highlights
The company hosted a dedicated session titled 'hADM as the Hero of the ECM Era,' focusing on its human-derived acellular dermal matrix (hADM) product Re2O. Presenters detailed foundational and clinical research outcomes, along with global safety management systems, drawing strong interest from attending physicians.
## Global Safety Standards
Faith P. Case, former Vice Chair of the American Association of Tissue Banks (AATB) Accreditation Committee, outlined rigorous U.S. standards for human tissue donation and distribution. She emphasized voluntary donation, donor verification, infectious disease testing, manufacturing process validation, and traceability systems, addressing ethical and safety concerns with scientific evidence.
## Clinical Applications and Expansion
Dr. Park Je-young of Oracle Dermatology Clinic in Apgujeong presented optimal injection strategies using Re2O's adjustable target depth. He noted that Re2O has been used in over 400,000 procedures domestically and internationally, accumulating safety and clinical reliability. He also suggested potential expansion into hair regeneration, fat volume restoration, and muscle activation.
## Skin Longevity Paradigm
Dr. Ahn Bong-kyun of My D Dermatology Clinic emphasized that maintaining skin tissue structure and function long-term is the future of treatment, beyond short-term cosmetic improvement. Dr. Yoon Seong-jae of Leaders Dermatology Clinic added that human-derived ECM naturally restores aged skin structure without foreign body reactions.
## What buyers should watch
For importers and distributors, L&C Bio's Re2O represents a clinically proven ECM therapy with over 400,000 procedures and growing indications. The company plans to expand its ECM-based treatment portfolio, making it a key product to monitor for clinics seeking advanced regenerative aesthetic solutions. Regulatory compliance with AATB standards also assures supply-chain safety.